PMID-31555601 – Thymosin Alpha-1: A Reappraisal in Cancer Therapy
Costantini C et al. "A Reappraisal of Thymosin Alpha1 in Cancer Therapy," Frontiers in Oncology, 2019;9:873.
Quick Reference
| Property | Value |
|---|---|
| PMID | 31555601 |
| DOI | 10.3389/fonc.2019.00873 |
| Year | 2019 |
| Journal | Frontiers in Oncology |
| Study Type | Narrative Review |
| Evidence Level | V |
| Sample | N/A (review) |
| Peptide(s) Studied | Thymosin Alpha-1 |
Key Findings
- Thymosin alpha-1 (Ta1) can convert immunologically "cold" tumors into "hot" tumors by enhancing immune cell infiltration into the tumor microenvironment
- Ta1 activates dendritic cells via TLR9 signaling, promoting cross-presentation of tumor antigens
- Synergistic effects demonstrated when combining Ta1 with immune checkpoint inhibitors (anti-PD-1/PD-L1)
- Ta1 enhances NK cell and cytotoxic T lymphocyte activity against tumor cells
- The peptide modulates the tumor microenvironment by shifting the balance from immunosuppressive (M2/Treg) to immunostimulatory (M1/Th1) phenotypes
- Clinical data from hepatocellular carcinoma and melanoma studies suggest improved outcomes when Ta1 is added to standard-of-care regimens
Study Design
Narrative review synthesizing preclinical and clinical data on thymosin alpha-1 in oncology. Covers mechanisms of immune activation, tumor microenvironment modulation, and combination strategies with checkpoint inhibitors and chemotherapy.
Limitations
- Narrative review without systematic methodology or quantitative synthesis
- Many cited studies are preclinical or early-phase clinical trials
- Heterogeneous tumor types and treatment combinations make generalizations difficult
- Publication bias toward positive results not assessed
Clinical Relevance
This review repositions thymosin alpha-1 as a potential cancer immunotherapy adjunct. The mechanistic rationale for combining Ta1 with checkpoint inhibitors is compelling, particularly for patients with immunologically cold tumors that do not respond to checkpoint blockade alone. Directly relevant for practitioners considering Ta1 in the context of cancer adjunct therapy, and for understanding the immune-modulating properties of Ta1 beyond infectious disease.
Related
#research #narrative-review #evidence-level-V #cancer